Autres langues Ribomic Inc.

Actions

4591

JP3974850004

Recherche biotechnologique et médicale

Marché Fermé - Japan Exchange 08:30:00 31/08/2026			Varia. 5j.	Varia. 1 janv.
95,00 ^JPY	+2,15%		+13,10%	+21,79%

24/08	Ribomic annonce la finalisation du réseau de centres pour l'essai clinique de phase 3 de l'umedaptanib pegol dans l'achondroplasie	CI
13/08	Ribomic Inc. publie ses prévisions de résultats non consolidés pour l'exercice clos le 31 mars 2027	CI

Autres langues

24/08	Ribomic Announces Completion of Clinical Trial Site Establishment for the Phase 3 Clinical Trial of Umedaptanib Pegol in Achondroplasia
13/08	Ribomic Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2027
13/08	Ribomic Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026
02/07	Ribomic Enrolls First Patient in Phase III Trials of Umedaptanib Pegol for Achondroplasia Treatment
02/07	Ribomic Inc. Announces First Patient Enrollment In Phase 3 Clinical Trial Of Umedaptanib Pegol For Achondroplasia
14/05	Ribomic Inc. Reports Earnings Results for the Full Year Ended March 31, 2026
19/03	Ribomic Files IND For Phase III Trial Of Achondroplasia Drug In Japan
19/03	Ribomic Inc Announces IND Application for Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia Treatment
10/03	Ribomic Reports Positive Phase II Results For Achondroplasia Drug
10/03	Ribomic, Inc. Announces Summary Report on Primary Endpoint for Phase Ii Clinical Trial of Umedaptanib Pegol in the Treatment of Achondroplasia
12/02	Ribomic Inc. Reports Earnings Results for the Nine Months Ended December 31, 2025
14/01	Ribomic Files Patent for Anti-Autotaxin Aptamer RBM-006
14/01	RIBOMIC, Inc. Announces New Substance Patent Application for Highly Active RBM-006 (Anti-Autotaxin Aptamer) and its Drug Impact in a Mouse Model of Diabetic Retinopathy
21/11	Ribomic Shows Sustained Two-Year Gains in Achondroplasia Trial
08/10/25	RIBOMIC veröffentlicht positive Ergebnisse der Phase-2-Kohorte 2 für Umedaptanib Pegol bei Achondroplasie, die eine Steigerung der annualisierten Wachstumsrate um bis zu +5,0 cm/Jahr bei zweiwöchentlicher Verabreichung bei Kindern ab 5 Jahren zeigen
07/10/25	Ribomic Reports Positive Phase 2 Results for Achondroplasia Drug Umedaptanib Pegol
07/10/25	Ribomic, Inc. Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of Up to +5.0 Cm/Year with Biweekly Administration in Children Aged 5 Years and Older
07/10/25	Ribomic announces positive phase 2 cohort 2 results for umedaptanib pegol in achondroplasia
07/10/25	RIBOMIC Announces Positive Phase 2 Cohort 2 Results for Umedaptanib Pegol in Achondroplasia, Demonstrating an Increase in the Annualized Growth Rate of up to +5.0 cm/year with Biweekly Administration in Children Aged 5 Years and Older
25/09/25	Ribibo, Inc. Announces Discovery of Therapeutic Effects of Umedaptanib Pegol in A Diabetic Retinopathy Model and New Patent Application for Use
20/08/25	Ribomic Reports Sustained Efficacy of Achondroplasia Drug in Long-Term Trial
20/08/25	RIBOMIC, Inc. Announces the Sustained Efficacy in A Long-Term Administration Trial of Umedaptanib Pegol for Achondroplasia
08/08/25	Ribomic Inc. announced that it has received ¥0.93 million in funding from Evolution Capital Management LLC
01/08/25	RIBOMIC Plans to Initiate Phase III Clinical Trial of Umedaptanib Pegol for Achondroplasia in 2026 Following the Ongoing Phase II Clinical Trial
23/07/25	Ribomic Inc. announced that it expects to receive ¥0.93 million in funding from Evolution Capital Management LLC